[CD45 phosphatase, a relevant target for the treatment of acute myeloid leukemia]

Med Sci (Paris). 2016 Dec;32(12):1051-1053. doi: 10.1051/medsci/20163212002. Epub 2017 Jan 3.

[Article in French]

Authors

Laetitia Saint-Paul¹, Chi-Hung Nguyen², Jean-Noël Bastie³, Laurent Delva¹, Ronan Quéré¹

Affiliations

¹ Inserm UMR866, Université Bourgogne-Franche-Comté, Faculté de médecine, 7, boulevard Jeanne d'Arc, 21000 Dijon, France - LipSTIC Labex, 21000 Dijon, France.
² Institut Curie, UMR9187-U1196, CNRS-Institut Curie, Inserm, Centre Universitaire, 91400 Orsay, France.
³ Inserm UMR866, Université Bourgogne-Franche-Comté, Faculté de médecine, 7, boulevard Jeanne d'Arc, 21000 Dijon, France - LipSTIC Labex, 21000 Dijon, France - Hôpital Universitaire François-Mitterrand, Service d'Hématologie Clinique, 21000 Dijon, France.

PMID: 28044962
DOI: 10.1051/medsci/20163212002

No abstract available

Publication types

News

MeSH terms

Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Granulocyte-Macrophage Colony-Stimulating Factor / physiology
Humans
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / immunology
Leukemia, Myeloid, Acute / metabolism
Leukocyte Common Antigens / antagonists & inhibitors
Leukocyte Common Antigens / immunology
Leukocyte Common Antigens / physiology*
Molecular Targeted Therapy*
Quinoxalines / pharmacology
Quinoxalines / therapeutic use*
Signal Transduction / immunology

Substances

Antineoplastic Agents
Quinoxalines
Granulocyte-Macrophage Colony-Stimulating Factor
Leukocyte Common Antigens
PTPRC protein, human